Recent Updates
Recently added Catalysts
KRYS Positive Sentiment Score: 75/100

Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Key Takeaway: Krystal Biotech, Inc. announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference, set for June 10, 2025, in Miami. CEO Krish S. Krishnan will engage in a fireside chat and lead investor meetings throughout the event. The company is noted for its focus on genetic medicines, particularly with its commercial product VYJUVEK® aimed at treating rare diseases. Interested parties can access a webcast of the presentation on the company's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Krystal Biotech will showcase its innovations at a prestigious conference.
  • The company's CEO will lead discussions, indicating strong leadership presence.
  • Krystal Biotech is recognized for its pioneering work in genetic medicines.

Full Press Release Details

PITTSBURGH, June 03, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, in Miami. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 2:00 pm ET and host investor meetings throughout the day.
A webcast of the presentation will be available here beginning at 2:00 pm ET on Tuesday, June 10, 2025 and will be posted on the Investors section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved by the FDA and EMA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
Investors and Media:

Frequently Asked Questions

When will Krystal Biotech participate in the Goldman Sachs conference?

Krystal Biotech will participate on June 10, 2025.

Who will represent Krystal Biotech at the conference?

Krish S. Krishnan, CEO and Chairman, will represent the company.

What is VYJUVEK® by Krystal Biotech?

VYJUVEK® is the first redosable gene therapy approved for dystrophic epidermolysis bullosa.

Where is Krystal Biotech headquartered?

Krystal Biotech is headquartered in Pittsburgh, Pennsylvania.

How can I view the presentation webcast?

The webcast will be available on the company’s website starting at 2:00 pm ET.

Last updated: Jun 3, 2025